3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Recruiting
2
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Polycythemia Vera
2
Thrombosis
1
Thrombocytosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Glioma
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Epstein-Barr Virus Infections
1
Bites and Stings
1
Adenocarcinoma Of Esophagus
1
Interventions
Cytarabine
85
Cyclophosphamide
58
Azacitidine
57
fludarabine
52
venetoclax
41
fludarabine phosphate
41
Busulfan
30
Filgrastim
23
Whole-Body Irradiation
22
Decitabine
21
Mycophenolic Acid
20
Methotrexate
19
Mitoxantrone
18
Etoposide
18
Antilymphocyte Serum
18
Cyclosporine
17
Clofarabine
17
Tacrolimus
16
Granulocyte Colony-Stimulating Factor
16
Peripheral Blood Stem Cell Transplantation
15
Daunorubicin
15
Melphalan
13
thymoglobulin
11
Thiotepa
11
Stem Cell Transplantation
11
Interleukin-2
11
Idarubicin
10
Gemtuzumab
9
Cord Blood Stem Cell Transplantation
9
aldesleukin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myeloid, Acute
×
Hydroxyurea
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts